Profile of:

John Reveille

Full name: John Reveille

Current country: United States

Membership level: Full

Type of membership: Advisory Board

Number of publications: 61

Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort (2024)

Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature (2023)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study (2023)

Quantitative proteomic screening uncovers candidate diagnostic and monitoring serum biomarkers of ankylosing spondylitis (2023)

The faecal microbiota is distinct in HLA-B27+ ankylosing spondylitis patients versus HLA-B27+ healthy controls (2023)

Why Do Some Patients Have Severe Sacroiliac Disease But No Syndesmophytes in Ankylosing Spondylitis? Data From a Nested Case-Control Study (2023)

Environmental Risks for Spondyloarthropathies (2022)

Correction: Stoll et al. Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients. Children 2022, 9, 569 (2022)

Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study (2022)

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study (2022)

Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients (2022)

Chronic inflammatory back pain commencing late in life: a neglected concept (2022)

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years (2022)

The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. (2021)

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years (2021)

Biomarkers in axial spondyloarthritis and low back pain: a comprehensive review (2021)

The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment (2021)

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthriti (2021)

Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis: A 15-year follow up study of the PSOAS Cohort (2021)

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis (2021)

HLA-B27 is associated with reduced disease activity in axial spondyloarthritis (2021)

Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis (2021)

Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry (2021)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y) (2021)

Single-cell analysis reveals innate immunity dynamics in ankylosing spondylitis. (2021)

Ankylosing spondylitis risk factors: a systematic literature review (2021)

Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis (2021)

The Effect of HLA-B27 on Susceptibility and Severity of COVID-19 (2021)

The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial (2021)

Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study (2021)

Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time (2020)

Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial (2020)

Correction to: The IgG galactosylation ratio is higher in spondyloarthritis patients and associated with the MRI score (2020)

The changing profile of ankylosing spondylitis in the biologic era (2020)

Content validity of the ASQoL for use in a non-radiographic axial spondyloarthritis population: a qualitative study (2020)

Biologics, spondylitis and COVID-1 (2020)

Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci (2020)

Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort (2020)

The IgG galactosylation ratio is higher in spondyloarthritis patients and associated with the MRI score (2020)

A rare variant of RNF123 in familial ankylosing spondylitis causes dysfunction of osteoclast formation (2020)

A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values (2020)

Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis (2020)

Reliability and Validity of Patient-reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis (2020)

Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis (2020)

IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis (2019)

Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis (2019)

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study (2019)

Genetic association of non-MHC region with ankylosing spondylitis in a Chinese population (2019)

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors (2019)

HLA class I and II alleles in susceptibility to ankylosing spondylitis (2019)

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled tria (2018)

Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort (2018)

Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis (2018)

A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits (2018)

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study (2018)

Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohor (2018)

Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups (2017)

Clinical patterns and characteristics of ankylosing spondylitis in China (2017)

Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study (2017)

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis (2017)

A family-based genome-wide association study reveals an association of spondyloarthritis with MAPK14 (2017)